« Back
Home /
Polyinosinic-polycytidylic acid

Polyinosinic-polycytidylic acid

Item no.	HY-107202-5mg
Manufacturer	MedChem Express
CASRN	24939-03-5
Amount	5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Formula	(C10H13N4O8P)x.(C9H14N3O8P)x
Citations	Biochem Biophys Res Commun. 2024 Feb 15, 149661.<br>Cancer Med. 2023 Jun 7.<br>Chem Biol Drug Des. 2023 Nov;102(5):1110-1120.<br>Chem Eng J. 2021 Aug 15;418:129392.<br>FASEB J. 2024 Mar 31.<br>SSRN. 2023 Apr 29.<br>Virol Sin. 2023 Aug 24;S1995-820X(23)00104-9.<br>Virol Sin. 2023 May 2;S1995-820X(23)00048-2.<br>Adv Funct Mater. 29 August 2022.<br>Liver Int. 2022 Oct 17.<br>Mol Ther Oncolytics. 25 August 2022.<br>Phytomedicine. 2021, 153495.<br>SSRN. 2021 Apr 26.<br>[1]Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738. <br>[2]Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293(5):1364-1369. <br>[3]Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223.<br>[4]Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101.<br>[5]Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364.<br>[6]Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11.<br>[7]Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794.
Smiles	O[C@H]1[C@@H](O[C@H](COP(O)(O)=O)[C@H]1O)N2C3=C(C(NC=N3)=O)N=C2.O[C@H]4[C@H](N5C(N=C(N)C=C5)=O)O[C@H](COP(O)(O)=O)[C@H]4O.[x].[x]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Poly(I:C)
Available
Product Description	Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis[1][2].
StorageTemperature	-20°C, 3 years (Powder)
Shipping	Blue Ice
Manufacturers Applications	COVID-19-anti-virus
MolecularWeight	N/A
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer; Infection; Inflammation/Immunology
Solubility	H2O : 50 mg/mL (ultrasonic)
Manufacturers Target	Bcl-2 Family; HSP; Interleukin Related; PKD; Toll-like Receptor (TLR)
Isoform	Bax; Bcl-2; HSP70; IL-13; IL-17
Pathway	Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5 mg

available

Request delivery time